At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 46 enrolled
Drug / intervention
RX-3117drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
In Brief
A Phase 2 clinical trial evaluating RX-3117 for Metastatic Pancreatic Cancer. Completed, enrolled 46 participants across 10 sites.
Detailed Summary
This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer. After completion of the Phase 1 portion, a Phase 2a study will be conducted using a 2 stage, open-label design, of RX 3117 and Abraxane® in combination to treat subjects with metastatic pancreatic cancer as first line therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Pancreatic Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJun 2017
Enrollment StartOct 2017
Primary CompletionOct 2019
Study CompletionNov 2019
TodayJul 2026
First PostedJun 16, 2017
Enrollment StartOct 2, 2017
Primary CompletionOct 1, 2019
Study CompletionNov 21, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.0 years ago
Interventions
RX-3117drug
RX-3117 will be administered orally in combination with Abraxane.